Drug Trial Radar · NCT07004296
A Study of HDM2005 in Patients With Advanced Solid Tumor
Last checked: Nov 19, 2026Latest source record: Jun 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
May 29, 2025
Primary completion
Jul 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study evaluating the efficacy, safety, and pharmacokinetics ofHDM2005 in participants with metastatic solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
HDM2005Drug
HDM2005 will be administered via IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicity (DLT) events (for dose escalation phase)Time frame: up to 21 days or 28 days following first dose
- Incident and severity of adverse events(for dose escalation phase)Time frame: Until 28 days after the last dose or initiation of a new antineoplastic therapy, whichever occurs first.
- Progression-free survival(PFS)(for dose expansion phase)Time frame: Approximately 30 months
- Objective Response Rate (ORR)(for dose expansion phase)Time frame: Approximately 18 months
- Recommended Phase 2 Dose (RP2D) (for dose expansion phase) Recommended Phase 2 Dose (RP2D) (for dose expansion phase) Recommended Phase 2 Dose (RP2D) (for dose expansion phase)Time frame: Approximately 30 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.